


# Lab on a Chip

Devices and applications at the micro- and nanoscale

rsc.li/loc



ISSN 1473-0197



ROYAL SOCIETY  
OF CHEMISTRY

Celebrating  
IYPT 2019

**PAPER**

Cees Otto, Séverine Le Gac *et al.*

Immuno-capture of extracellular vesicles for individual multi-modal characterization using AFM, SEM and Raman spectroscopy


 Cite this: *Lab Chip*, 2019, 19, 2526

# Immuno-capture of extracellular vesicles for individual multi-modal characterization using AFM, SEM and Raman spectroscopy†

 Pepijn Beekman, <sup>‡,ab</sup> Agustin Enciso-Martinez, <sup>‡,c</sup> Hoon Suk Rho, <sup>bd</sup>  
Sidharam Pundlik Pujari, <sup>a</sup> Aufried Lenferink,<sup>c</sup> Han Zuilhof, <sup>ae</sup>  
Leon W. M. M. Terstappen,<sup>c</sup> Cees Otto <sup>‡,\*c</sup> and Séverine Le Gac <sup>‡,\*b</sup>

Tumor-derived extracellular vesicles (tdEVs) are promising blood biomarkers for cancer disease management. However, blood is a highly complex fluid that contains multiple objects in the same size range as tdEVs (30 nm–1 μm), which obscures an unimpeded analysis of tdEVs. Here, we report a multi-modal analysis platform for the specific capture of tdEVs on antibody-functionalized stainless steel substrates, followed by their analysis using SEM, Raman spectroscopy and AFM, at the single EV level in terms of size and size distribution, and chemical fingerprint. After covalent attachment of anti-EpCAM (epithelial cell adhesion molecule) antibodies on stainless steel substrates, EV samples derived from a prostate cancer cell line (LnCAP) were flushed into a microfluidic device assembled with this stainless steel substrate for capture. To track the captured objects between the different analytical instruments and subsequent correlative analysis, navigation markers were fabricated onto the substrate from a cyanoacrylate glue. Specific capture of tdEVs on the antibody-functionalized surface was demonstrated using SEM, AFM and Raman imaging, with excellent correlation between the data acquired by the individual techniques. The particle distribution was visualized with SEM. Furthermore, a characteristic lipid–protein band at 2850–2950 cm<sup>-1</sup> was observed with Raman spectroscopy, and with AFM the size distribution and surface density of the captured EVs was assessed. Finally, correlation of SEM and Raman images enabled discrimination of tdEVs from cyanoacrylate glue particles, highlighting the capability of this multi-modal analysis platform for distinguishing tdEVs from contamination. The trans-instrumental compatibility of the stainless steel substrate and the possibility to spatially correlate the images of the different modalities with the help of the navigation markers open new avenues to a wide spectrum of combinations of different analytical and imaging techniques for the study of more complex EV samples.

 Received 24th January 2019,  
Accepted 27th May 2019

DOI: 10.1039/c9lc00081j

rsc.li/loc

<sup>a</sup> Laboratory of Organic Chemistry, Wageningen University, The Netherlands

<sup>b</sup> Applied Microfluidics for BioEngineering Research, MESA+ Institute for Nanotechnology and TechMed Center, University of Twente, The Netherlands. E-mail: s.legac@utwente.nl

<sup>c</sup> Medical Cell BioPhysics, TechMed Center, University of Twente, The Netherlands. E-mail: c.otto@utwente.nl

<sup>d</sup> Department of Instructive Biomaterials Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, The Netherlands

<sup>e</sup> School of Pharmaceutical Sciences and Technology, Tianjin University, 92 Weijin Road, Tianjin, China

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c9lc00081j

‡ These authors contributed equally to this work

## Introduction

Liquid biopsies have been proposed as an alternative to conventional approaches (*e.g.*, magnetic resonance imaging or solid biopsies) for the disease management of cancer patients. In this non-invasive approach, a blood sample (7.5 ml) is analyzed for the presence and amount of circulating tumor cells (CTCs), tumor-derived EVs (tdEVs), cell free DNA (cf-DNA), miRNA and/or tumor-associated proteins or peptides.<sup>1,2</sup> CTCs are well suited to characterize a tumor and to evaluate the heterogeneity for subsequent selection of the optimal treatment.<sup>3</sup> The concentration of CTCs is however extremely low (~1 CTC ml<sup>-1</sup>), especially when compared with that of blood cells (~10<sup>9</sup> ml<sup>-1</sup>).<sup>4</sup> In contrast, tdEVs are much more abundant with concentrations up to 10<sup>10</sup> tdEVs ml<sup>-1</sup>.<sup>5</sup> Importantly, the presence and amount of tdEVs in blood has been



proven to strongly correlate with the survival of patients with metastatic prostate cancer.<sup>6</sup> EVs are membrane-bound biological carriers of biomolecules, which are shed by all cell types. They are found in all body fluids,<sup>7</sup> and exhibit a size ranging from 30 nm to 1  $\mu\text{m}$ .<sup>8,9</sup> EVs are of great interest because of their implication in intercellular communication and pathogenesis;<sup>7,10,11</sup> they show great promises not only for disease diagnosis but also for drug delivery.<sup>4,11–13</sup> Altogether, EV analysis offers a promising approach for non-invasive cancer patient management as a result of the wealth of biological information they carry, some of which being potential biomarkers.<sup>14</sup>

However, blood is a highly complex fluid<sup>15</sup> that contains lipoproteins, cell debris and protein aggregates, as well as EVs of non-cancerous origin, which are all in the same size and density range as tEVs, and the same applies for less complex samples originating from cell culture media. In all these cases, tEVs need to be selectively isolated and/or distinguished from EVs of non-cancerous origin and other small objects.<sup>16,17</sup> Several methods have been proposed for EV isolation, among which ultracentrifugation and size-exclusion chromatography are the most popular.<sup>8,16,18–20</sup> However, these isolation approaches yield highly heterogeneous samples containing tEVs, other EVs, cell debris and molecular aggregates. Therefore, alternative approaches have been introduced that rely on the immuno-capture of targeted EVs, using either generic membrane markers (*e.g.*, CD9, CD63 and CD81) to retrieve all exosomes/EVs from a sample,<sup>21,22</sup> or specific membrane markers (*e.g.*, EpCAM,<sup>6</sup> EGFR,<sup>12</sup> HER2<sup>23</sup>) to selectively isolate tEVs. Microfluidic technology has proven to be instrumental for the immunocapture of EVs by controlling the surface dynamics (*e.g.*, controlling flow rate when washing non-specifically bound species), and drastically reducing the distances over which EVs have to migrate before coming in contact with the functionalized surface. In addition, microfluidics facilitates controlled and sequential handling of (very small amounts of) samples.<sup>8,24</sup>

A second main challenge is the high heterogeneity found in any purified EV sample, in terms of size and from a molecular perspective. Therefore, EVs must be thoroughly characterized for their possible and reliable recognition in heterogeneous samples. For that purpose, it is important to study individual EVs and not populations to avoid that ensemble averaging obscures differences. EVs have been analyzed using a great variety of techniques<sup>25–28</sup> such as flow cytometry,<sup>29–31</sup> confocal and non-confocal (fluorescence) microscopy,<sup>22,32</sup> scanning electron microscopy (SEM),<sup>33</sup> atomic force microscopy (AFM),<sup>34</sup> Raman spectroscopy,<sup>35</sup> surface plasmon resonance (SPR),<sup>36,37</sup> mass spectrometry (MS)<sup>38</sup> and micro nuclear magnetic resonance ( $\mu\text{NMR}$ ).<sup>39</sup> However, not all techniques allow the collection of information at the single EV level. Furthermore, to get comprehensive information on heterogeneous samples, different techniques yielding complementary information must be combined. In that context, Raman spectroscopy, SEM and AFM are of great interest. Raman spectroscopy provides chemical information on a sam-

ple of interest in a label-free manner.<sup>40,41</sup> SEM enables characterization of the size and morphology of intact EVs.<sup>42,43</sup> Correlating this size and morphology information with Raman fingerprints confirms the cellular origin of individual EVs, and, in previous work, we have demonstrated that using this combination cancer cells could be distinguished from non-cancer cells.<sup>44,45</sup> Finally, AFM yields more detailed information on the size and morphology of EVs, and possibly, on their mechanical properties.<sup>30,46</sup>


In this paper, we report the specific isolation of tEVs obtained from a human prostate cancer cell line (LNCaP) on functionalized stainless-steel substrates followed by their *in situ* multi-modal characterization with SEM, Raman and AFM imaging (Fig. 1). Stainless steel substrates were selected for their suitability for all considered modalities: this material gives little background in Raman (see ESI 1<sup>†</sup>);<sup>44,45</sup> it is conductive; and mirror-polished stainless steel substrates have a low surface roughness level of *ca.* 7 nm, which is well-suited for the analysis of EVs by AFM. Here, and as depicted in Fig. 2, stainless steel substrates were first functionalized with a monolayer of carboxydecyl phosphonic acid (CDPA),<sup>47–49</sup> onto which antibodies targeting tEVs were covalently anchored through carbodiimide-based bioconjugation chemistry.<sup>50</sup> The resulting monolayers were characterized with X-ray photoelectron spectroscopy (XPS) and infrared reflection-absorption spectroscopy (IRRAS), to optimize their formation with respect to the initial CDPA concentration. Next, LNCaP-derived EVs were injected in a microfluidic channel assembled onto the functionalized stainless steel substrate, for their capture, which was confirmed using individual imaging techniques. For their multi-modal analysis, and to easily track individual EVs in the different instruments, navigation markers were fabricated on the functionalized substrates next to a region of interest (ROI). Finally, the captured EVs were successively analyzed by Raman imaging, SEM, and AFM, and data acquired by the different techniques correlated. The trans-instrumental compatibility of the stainless steel substrate and the tracking possibility offered by the navigation markers give the opportunity to apply a wide spectrum of combinations of different analytical and imaging techniques.

## Experimental


### Materials

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), *N*-hydroxysuccinimide (NHS), acetone (VLSI grade), paraformaldehyde (PFA), phosphate-buffered saline (PBS), and 2-(*N*-morpholino)ethanesulfonic acid were purchased from Merck (Zwijndrecht, The Netherlands). Ethanol (VLSI grade) and dichloromethane were purchased from VWR (Amsterdam, The Netherlands). Carboxydecyl phosphonic acid (CDPA) was purchased from Sikémia (Montpellier, France). Sylgard 184 poly(dimethylsiloxane) (PDMS) was purchased from Farnell (Utrecht, The Netherlands). SS316L Stainless steel foils (0.9 mm thickness, one side mirror polished) were purchased





**Fig. 1** Multi-modal analysis of tdEVs on antibody-functionalized stainless steel substrates. After their selective capture on a stainless steel substrate functionalized with antibodies of interest (here anti-EpCAM antibodies targeting tdEVs), EVs are successively imaged using Raman spectroscopy, SEM and AFM, and information collected from these different imaging modalities correlated to get a comprehensive picture on the captured objects.



**Fig. 2** Different steps of surface modification and capture of the tdEVs on stainless steel substrates. a) An oxygen plasma-treated stainless steel substrate is functionalized with a carboxydecyl phosphonic acid (CDPA) monolayer. b) Anti-EpCAM antibodies are conjugated to the CDPA monolayer using NHS/carbodiimide chemistry. c) tdEVs (in green here) are specifically immuno-captured on the antibody-functionalized surface. d) The substrate is washed to remove non-specifically bound materials (in red and purple here), before retained EVs are fixed and dehydrated.

from Goodfellow Inc. (Bad Nauheim, Germany). Anti-EpCAM antibodies were produced at the University of Twente, The Netherlands (Medical Cell Biophysics Laboratory) from VU1D9 hybridoma cells.


### PDMS handling devices

Three different PDMS devices (a 6 mm diameter reservoir, a xurography channel and a navigation marker device) were used for different steps of the sample preparation, as depicted in Fig. 3. For all devices, PDMS was prepared and cured according to the same procedure. PDMS precursor and cross linker (10:1 weight ratio) were first thoroughly mixed, and subsequently degassed by centrifugation at  $1000 \times g$  for 1 min. The resulting mixture was poured on different molds for the different devices, and degassed again in a desiccator for 15 min. Curing was performed at  $80 \text{ }^\circ\text{C}$  overnight.

**PDMS reservoir.** A large 6 mm diameter PDMS reservoir was used for the antibody immobilization onto CDPA-functionalized stainless steel substrates. To this end, a 5 mm height PDMS layer was prepared in a Petri dish. This PDMS layer was cut in  $1 \times 1 \text{ cm}^2$  pieces, in which a hole was punched with a Harris Uni-Core 6 mm biopsy punch (VWR International B.V., Amsterdam, The Netherlands).

**Xurography channel.** To capture EVs and their subsequent washing and fixation, a xurography microchannel was used. The mold for this device was produced using a desktop plotter (Silhouette Cameo 2, Silhouette, Watingen), as follows. First, a  $6 \text{ mm} \times 3 \text{ mm}$  feature was cut out of a foil laminated with a  $200 \text{ }\mu\text{m}$  thick adhesive layer, and subsequently placed at the bottom of a clean Petri dish. The foil was removed to only leave the adhesive layer. After PDMS curing in this mold, inlets and outlets were punched using a 1 mm diameter Harris Uni-Core biopsy punch. The resulting device was placed on top of a stainless steel substrate after removal of the previously used PDMS reservoir.





**Fig. 3** Various PDMS devices used in this work. Top, and from left to right: 6 mm diameter reservoir used for the immobilization of antibodies under static conditions on a CDPA monolayer; xurography microchannel ( $6 \times 3 \times 0.2 \text{ mm}^3$ ) used for the capture of EVs and subsequent washing under mild flow conditions ( $400 \mu\text{l min}^{-1}$ ); microfluidic device used for the fabrication of navigation markers next to a  $50 \mu\text{m} \times 1 \text{ mm}$  sample region, subsequently considered for analysis using SEM, Raman and AFM. Bottom, right: Design of the microfluidic device used to fabricate the navigation markers, consisting of three microfluidic channels, two microchannels comprising pillars with various geometries, flanking one sample microchannel, all channels being  $30 \mu\text{m}$  height  $\times$   $50 \mu\text{m}$  width  $\times$   $1 \text{ mm}$  length, and (Left) actual SEM image showing the navigation markers fabricated from cyanoacrylate glue injected in the side-channels and used to retrace the captured objects in the different imaging instruments.

**Navigation marker device.** For the multi-modal analysis, and after dehydration of the captured EVs (see section “Vesicle capture and dehydration”), navigation markers were fabricated on the stainless steel substrates for easy tracking of the captured EVs, using a microfluidic device comprising 3 microchannels: two microchannels featuring navigation markers (Fig. 3) and flanking one sample channel. All channels were  $30 \mu\text{m}$  height  $\times$   $50 \mu\text{m}$  width  $\times$   $1 \text{ mm}$  length. The distance between the navigation markers and the sample region ( $80 \mu\text{m}$ , center-to-center) was chosen to be compatible with the characteristic dimension of the field of view of the bright-field optical objectives in all instruments used in this work (*i.e.*,  $\sim 200 \mu\text{m}$  for the Raman system,  $500 \mu\text{m}$  for the AFM instrument and freely variable in the SEM, see ESI 2<sup>†</sup>).

The design of this microfluidic device was drawn in CleWin (WieWeb, Hengelo, The Netherlands), and the mold fabricated in the Nanolab cleanroom of the MESA+ Institute for Nanotechnology. Briefly, a  $\langle 100 \rangle$  Si wafer was spin-coated with AZ-40XT resist (Microchemicals, Ulm, Germany) at 3000 RPM for 1 min to yield a  $30 \mu\text{m}$  thick layer. The photoresist was exposed, baked and developed according to the manufacturer's specifications. After PDMS casting on the finished mold, fluidic accesses were punched using a 1 mm diameter Harris Uni-Core biopsy punch. The PDMS device was placed on top of a functionalized stainless steel substrate after EV capture and dehydration. No specific care was required for alignment of the device, since the width of the

sample region is much smaller than that of the xurography channel. Cyanoacrylate superglue (Tesa SE, Norderstedt, Germany) was injected in the side channels and cured for 30 min to create the navigation markers. After PDMS delamination, the designed micro-features were transferred to the stainless steel surface with high fidelity (Fig. 3, bottom left).

### CDPA monolayer formation and characterization on stainless steel substrates

**CDPA monolayer formation.** Stainless steel substrates were laser-cut into  $1 \text{ cm} \times 1 \text{ cm}$  substrates and cleaned in an ultrasonic bath in ethanol, acetone and dichloromethane (7 min for each solvent), followed by an oxygen plasma treatment for 3 min in a Diener Pico (Diener electronic, Bielefeld, Germany) at 250 W. Immediately after plasma treatment, the substrates were transferred to a solution of CDPA in ethanol for overnight incubation at  $60 \text{ }^\circ\text{C}$  to form a CDPA monolayer (Fig. 2a). Three CDPA concentrations were initially tested (0.1, 1 and 10 mM) to identify the optimal concentration. The resulting CDPA monolayer was subsequently cured in a vacuum oven at  $130 \text{ }^\circ\text{C}$  for 1 h and finally washed in an ultrasonic bath in ethanol, acetone and dichloromethane (7 min for each solvent).

**Infrared reflection/absorption spectroscopy (IRRAS).** IRRAS measurements were performed on a Bruker Tensor 27 using a Harrick Auto Seagull™ (Bruker Nederland B.V.). 2000 scans per measurement were recorded under an angle of incidence of  $83^\circ$  using a liquid nitrogen-cooled MCT (mercury-cadmium-telluride) detector. Measurements were taken in triplicates after 35 min of purging with argon to remove moisture and carbon dioxide. Data were averaged and normalized with respect to a reference ( $\text{O}_2$  plasma-cleaned stainless steel) to yield relative absorption values.

**X-ray photoelectron spectroscopy (XPS).** XPS measurements were conducted on a JPS-9200 (JEOL, Japan) under ultra-high vacuum conditions with analyser pass energy of 10 eV using monochromatic  $\text{Al K}\alpha$  X-ray radiation at 12 kV and 20 mA at an angle of incidence of  $80^\circ$ . Wide scans (0–800 eV) were recorded as well as narrow scans in the 280–300 eV region to more closely inspect the carbon binding energies.

### Antibody conjugation onto the CDPA monolayer

Anti-EpCAM antibodies were conjugated onto the CDPA monolayer using EDC/NHS chemistry at room temperature (Fig. 2b). In the PDMS reservoir, a solution of 40 mM NHS, 130 mM EDC and 50 mM 2-(*N*-morpholino)ethanesulfonic acid in Milli-Q (pH 5) was pipetted and left to react with the CDPA monolayer for 30 min. The substrate was subsequently rinsed with  $50 \mu\text{l}$  of a 5 mM acetic acid solution in Milli-Q to stop the reaction, followed by  $100 \mu\text{l}$  PBS. Next, the antibody solution at  $20 \mu\text{g ml}^{-1}$  in PBS was pipetted in the reservoir and incubated with the surface for 1 h, followed by extensive washing with PBS to remove unreacted chemicals. Finally, unreacted NHS ester groups were



blocked by a 0.1 M ethanolamine solution in Milli-Q for 30 min. The reservoirs were filled with PBS buffer until their use within 24 h.

### Vesicle capture and dehydration

EVs were isolated from culture medium (see ESI 3† for the isolation protocol) of the human prostate cancer cell line LNCaP, which is known to express epithelial cell adhesion molecules (EpCAM). To avoid any EV contamination from the serum added to the culture medium, the LNCaP cells were cultured in serum-free medium for 48 h before their isolation. Nanoparticle tracking analysis (NTA)<sup>51</sup> of those isolated EVs revealed a concentration of  $1.06 \times 10^9$  EVs  $\text{ml}^{-1}$  (see ESI 4†). 25  $\mu\text{l}$  of this EV-containing suspension was introduced into the xurography channel (channel volume: 3.6  $\mu\text{l}$ ) using a capillary pipette tip acting as an inlet reservoir, and left under static incubation for 1 h at room temperature. Channels were subsequently washed with 200  $\mu\text{l}$  of PBS at a flow-rate of 400  $\mu\text{l min}^{-1}$  using a syringe-pump connected to the outlet reservoir and operated in withdrawal mode (Fig. 2d). Captured EVs were next fixed in the channel with a 1% PFA solution in PBS. After fixation of the EVs, the PDMS device was removed, the sample rinsed in Milli-Q, dehydrated by immersion in a solution of 70% ethanol in Milli-Q (5 min) followed by immersion in pure ethanol (5 min), and finally dried overnight under ambient conditions. Various negative control experiments were conducted in this study, as summarized in Table ESI 1:† (i) no activation of the CDPA layer with EDC/NHS; (ii) no immobilization of anti-EpCAM antibodies; and (iii) no incubation with any EV sample.

### Multi-modal analysis of the captured EVs on anti-EpCAM-conjugated stainless steel substrates

**SEM measurements.** SEM imaging was performed using a JEOL JSM-6610LA Analytical SEM (JEOL, Nieuw-Vennep, The Netherlands). The SEM was operated in high-vacuum mode, and images were recorded with secondary electron (SE) detection with a low acceleration voltage of 2 kV to avoid sample charging in the absence of conductive coatings.

**Raman measurements.** Hyperspectral Raman microspectroscopy was performed by 2D point scanning of a laser beam ( $\lambda = 647.09$  nm) from a Coherent Innova 70C laser. The Raman scattered light was dispersed in a spectrometer and collected with a CCD sensor (Andor Newton DU-970-BV). The wavenumber interval per pixel is  $\sim 2.3$   $\text{cm}^{-1}$  on average over the length of the sensor. The laser power was measured underneath the objective (40 $\times$ , NA: 0.95) and adjusted to 10 mW. The laser focal spot ( $d \sim 0.39$   $\mu\text{m}$ ,  $h \sim 1.2$   $\mu\text{m}$ ) was focused on the substrate and a 30  $\mu\text{m} \times 30$   $\mu\text{m}$  ROI was scanned with a step size of 0.47  $\mu\text{m}$  and an illumination time of 250 ms per pixel. Using MATLAB 2017b (Mathworks, Eindhoven, The Netherlands), after wavenumber and intensity calibration, the data were pre-treated by cosmic ray removal and noise reduction by singular value decomposition, maintaining five singular components. Raman spectra were

acquired across the entire wavenumber range (0–3660  $\text{cm}^{-1}$ ). Multivariate analysis by means of principal component analysis (PCA) was performed in the high frequency spectral region between 2700 to 3200  $\text{cm}^{-1}$ . PCA was used to extract the most relevant information from the data matrix and to represent it as a linear combination of orthogonal principal components (PC or loadings) with coefficients (scores) for the contribution of the variance to the data.<sup>52</sup> For each loading, a single score value was assigned to each measured pixel in the ROI and a Raman image reconstructed based on the scores. A high score value for a certain loading means a high contribution of that loading to the corresponding pixel.


**AFM measurements.** AFM measurements were performed on an Asylum MFP-3D instrument (Asylum Research, Santa Barbara, USA) in AC air topography mode (*i.e.*, tapping mode) with a scan rate of 0.1 Hz and a set point of 400 mV. An Olympus micro cantilever with a nominal spring constant of 2 N  $\text{m}^{-1}$  was used (resonant frequency  $\sim 70$  kHz). The resulting graphs were processed with Gwyddion 2.5.1 SPM analysis software ([www.gwyddion.net](http://www.gwyddion.net)). A mean plane subtraction and 3<sup>rd</sup> order polynomial background removal was applied. For object analysis, a  $25.0 \pm 0.2$  nm height threshold was applied to the data and circles were fitted to the remaining islands. A list of radii was exported to MATLAB 2016a (Mathworks, Eindhoven, The Netherlands) for analysis and plotting of a size distribution histogram.

## Results and discussion

### Monolayer formation and characterization

To optimize the monolayer formation, different concentrations of carboxydecyl phosphonic acid (CDPA) were tested and the resulting CDPA monolayers analyzed using IRRAS to evaluate the surface coverage, molecular ordering, and the configurations of the carboxyl groups. Spectra recorded for stainless steel substrates functionalized with CDPA (1 mM solution), as well as for CDPA powder, are presented in Fig. 4a. Bands assigned to the anti-symmetric  $\text{CH}_2$  stretch were found around 2914  $\text{cm}^{-1}$  for all tested CDPA concentrations (see ESI 5†). These anti-symmetric  $\text{CH}_2$  stretch bands are typically found between 2914 and 2930  $\text{cm}^{-1}$ , and their exact values reflect the packing density of the monolayer. Low values, as observed here, suggest densely packed monolayers displaying a short-range inter-chain monolayer ordering.<sup>47,48,53–56</sup> In all samples, the carboxyl band was detected at  $\sim 1720$   $\text{cm}^{-1}$ , which is attributed to acyclically dimerized carboxyl groups,<sup>57</sup> *i.e.*, hydrogen-bonding dimerization with nearest neighbors. Higher absorption frequencies for this band (towards 1740  $\text{cm}^{-1}$ ) indicate non-hydrogen-bonded species, and therefore a less dense monolayer. Lower frequencies ( $\sim 1700$   $\text{cm}^{-1}$ ) would suggest cyclic dimerization as a result of multilayer formation. In the 1700–1740  $\text{cm}^{-1}$  region, peak broadening was observed in the substrates functionalized with 0.1 and 10 mM solutions (see ESI 5†), indicating a lesser degree of ordering than for the substrates prepared with a 1 mM solution. The





**Fig. 4** Chemical characterization of the stainless steel surfaces after the different surface modification steps. a) IRRAS spectra (which are background corrected) of CDPA monolayers prepared on SS316L stainless steel substrates using a 1 mM CDPA solution (blue trace) and CDPA powder (red trace). b) XPS spectra recorded after the various surface modification steps, as depicted in Fig. 2. Wide range scans acquired on a  $O_2$  plasma-treated stainless steel substrate (SS, black trace), a stainless steel substrate functionalized with a CDPA monolayer (SS + CDPA, red trace); and after antibody conjugation on the CDPA monolayer (SS + CDPA + AB, blue trace). c) C 1s narrow scan showing fitted peaks corresponding to the different carbon species found in a CDPA molecule (inset).

baseline across the relative samples revealed that the signal-to-noise ratio for the substrate prepared with a 1 mM solution was also significantly improved compared to the other samples. Therefore, on the basis of these results, further experiments were conducted using a 1 mM CDPA solution for the 1<sup>st</sup> step functionalization of the stainless steel substrates.

After each surface modification step (oxygen plasma treatment, CDPA functionalization, antibody modification), the substrates were also analyzed using XPS (Fig. 4b). Integration of the peak surface areas provides quantitative information about the proportion of elements found on the substrate. After  $O_2$  plasma (black line, Fig. 4b), relatively little carbon (C 1s signal at  $\sim 285$  eV) was found on the stainless steel substrates, and this corresponds to adventitiously adsorbed carbon. A significant oxygen peak (O 1s peak at 532 eV) was detected as a result of the plasma treatment. Finally, various metals were present, such as Fe 2p (710 eV) and Cr 2p (575 eV). After formation of the CDPA monolayer, the signal corresponding to carbon became more intense, and a peak appeared at 134 eV, corresponding to P 2p. Integration of these two peaks reveals a C:P ratio of 11.2:1, which is in excellent agreement with the theoretically expected 11:1 ratio according to the molecular formula of CDPA (Fig. 4c). Carbon atoms experiencing different electronic environments are

characterized by different binding energies, and CDPA molecules comprise carbon atoms in three distinct environments, as depicted in Fig. 4c. The C atom in the carbonyl group is observed at  $\sim 289$  eV; the phosphorous-bound carbon at  $\sim 286.2$  eV; and the alkyl chain carbon atoms at 285 eV. Integrating these different C 1s signals yields a ratio of  $\sim 8.8:1.1:1$ , which is again in good agreement with the molecular structure of CDPA (9:1:1).

After formation of the monolayer (red line, Fig. 4b), signals originating from the metal elements decreased by a factor of  $\sim 1.5$ , indicating successful coverage of the surface by the CDPA monolayer. Using these XPS data, the monolayer thickness can be derived, together with the tilt angle of the CDPA molecules on the surface. The thickness ( $t$ ) of the CDPA layer was calculated using

$$t = -\lambda \times \sin \theta \times \ln \left( \frac{Fe_{CDPA}}{Fe_0} \right)^{58,59}$$


with  $\lambda$  being the attenuation length estimated for Fe 2p (1.4 nm),  $\theta = 80^\circ$ , and  $Fe_0$  and  $Fe_{CDPA}$  the signal intensities (counts per s) for Fe 2p before and after grafting of the CDPA monolayer, respectively. A CDPA monolayer thickness of  $1.2 \pm 0.1$  nm was found. Considering a molecular length of 1.30 nm for CDPA as determined by Chem3D (PerkinElmer Informatics, Inc.), this monolayer thickness corresponds to a tilt angle of  $20 \pm 10^\circ$ , which supports the IRRAS data that suggested the formation of a densely packed and ordered monolayer.


Finally, after antibody conjugation (Fig. 4b, blue line), an N 1s signal appeared at 400 eV. The metal signal was further attenuated, which can be accounted for by the formation of a thicker layer on the substrates due to the size of the antibody molecules, which is in the same order of magnitude as the probing depth of the technique, *i.e.*,  $\sim 10$  nm.

#### Capture of LNCaP-derived EVs on antibody-conjugated stainless steel substrates and uncorrelated analysis

The antibody-conjugated surfaces were incubated with an EpCAM-positive tdEV sample prepared from LNCaP culture medium, and subsequently imaged with SEM to demonstrate their ability to immuno-capture tdEVs. As shown in Fig. 5a, tdEVs were successfully and specifically captured on the antibody-conjugated stainless steel surfaces, onto which quasi-spherical objects in the 100 nm–1  $\mu$ m size range were identified. In contrast, in negative controls, for which one step of surface functionalization was omitted or which were not exposed to tdEV sample (see Table ESI 1, and Fig. ESI 6<sup>†</sup>), nothing was captured in the surface (Fig. 5a). Collectively, this experiment demonstrates the ability of our antibody-functionalized stainless steel substrates to successfully capture tdEVs.

As a next step, the same substrates, after capture of the tdEVs, were analyzed using Raman spectroscopy and AFM imaging. Hyperspectral Raman images were acquired on  $30 \mu\text{m} \times 30 \mu\text{m}$  ROIs ( $64 \times 64$  pixels), and analyzed using PCA in the spectral region between 2700 to 3200  $\text{cm}^{-1}$  that contains the most intense peaks. EVs were identified as regions with





**Fig. 5** Analysis of the tdEVs captured on anti-EpCAM functionalized stainless steel substrates. **a**) SEM imaging revealing the specific capture of tdEVs (obtained from LNCaP cells) on anti-EpCAM functionalized stainless steel substrates (top left), while no object was captured on negative control samples (top right; without carbodiimide/NHS activation; bottom left; without functionalization with anti-EpCAM antibodies; and bottom right, without exposure to tdEV samples). **b**) Mean Raman spectrum (black line) and standard deviation (shaded area) of all EVs segmented from the ROI presented in the inset (30 μm × 30 μm and 64 × 64 pixels). The Raman spectrum (Raman shift range 2700–3200 cm<sup>-1</sup>) shows a lipid–protein band (2850–2950 cm<sup>-1</sup>) with a characteristic peak at 2851 cm<sup>-1</sup>, which corresponds to the CH<sub>2</sub> symmetric stretch of lipids. In the inset, yellow pixels correspond to EVs and blue to the background. **c**) Size distribution of the surface-immobilized LNCaP-derived EVs determined by AFM (red histogram), and of the same sample in suspension before its immobilization on the surface as determined by NTA (blue line). Histogram: bin width 30 nm, error bars corresponding to the standard deviation ( $n = 5$ ). Inset: Mask used for counting EVs on the AFM image, showing all objects detected with a height greater than 25 nm.

pixels of high intensity values in certain scores. Such pixels were next segmented and used not only as a mask to identify the locations corresponding to EVs in all the images, as depicted in the inset of Fig. 5b, but also to compute a mean Raman spectrum for EVs, as presented in Fig. 5b. This spec-

trum comprises a characteristic lipid–protein band at 2850–2950 cm<sup>-1</sup>, and a clear peak at 2851 cm<sup>-1</sup> that corresponds to the CH<sub>2</sub> symmetric stretch of lipids.<sup>60</sup>

Finally, AFM images were used for quantitative analysis of the captured EVs. In five considered areas of 50 μm × 50 μm,






a total of  $5.4 \times 10^3$  tdEVs were detected, which corresponds to a surface density of  $4.3 \times 10^5$  tdEVs  $\text{mm}^{-2}$ . These objects presented a size range of 54 to 3840 nm and an average diameter of  $101 \pm 111$  nm, and Fig. 5c shows the particle distribution up to 0.7  $\mu\text{m}$ , since most of the particles were found in the 0–0.7  $\mu\text{m}$  range. Noteworthy, the particle size distribution and average size as determined by AFM were overall in good agreement with data obtained using nanoparticle tracking analysis (NTA), with yet a slight shift in the size distribution *i.e.*,  $167 \pm 91$  nm (see ESI 4† and Fig. 5c, blue line). The difference observed can be accounted for by the lower detection limit of the latter technique, or by shrinking of the EVs due to dehydration before multi-modal analysis.<sup>51,61</sup>

### Multi-modal analysis using SEM, Raman and AFM imaging

Finally, tdEVs captured on functionalized stainless steel substrates were analyzed successively using SEM, Raman and AFM imaging for their multi-modal characterization, and this last series of analysis was performed after fabrication of navigation markers on the stainless steel substrates. To identify interesting ROIs, the samples were first analyzed with SEM at a low resolution. It should be noted that for this first step of SEM imaging, the ROIs were not extensively exposed to the electron beam to avoid electron beam-induced deposition of amorphous carbon,<sup>62</sup> which would hinder later analysis by Raman spectroscopy. Next, the distance between the measured location and the nearest set of markers was noted so as to find back the same region in the different imaging techniques. Following this, the same ROIs on the surface were successively imaged using hyperspectral Raman spectroscopy and SEM to characterize the EV size and morphology. Similarly, and with the help of the navigation markers, the ROIs were traced back and imaged with AFM. A key element in this multi-modal analytical process is the presence of navigation markers: due to their varying pitch, size and shape, each location in the sample region, as defined by the microchannel in the last PDMS device, can be matched to a unique combination of markers to assign spatial reference points to a ROI. This reference enables to



**Fig. 6** Multi-modal analysis of LnCAP-derived EVs on anti-EpCAM functionalized stainless steel substrates. a) SEM image of a selected ROI (30  $\mu\text{m} \times 30 \mu\text{m}$ ). b) Corresponding AFM height image of the same ROI. c) AFM-SEM overlaid image. d) Raman spectrum in the 2700–3200  $\text{cm}^{-1}$  region of the PC3 displaying a characteristic lipid–protein band (2850–2950  $\text{cm}^{-1}$ ) specific to EVs, with a characteristic peak at 2851  $\text{cm}^{-1}$ , which corresponds to the  $\text{CH}_2$  symmetric stretch of lipids. e) Raman image of scores on PC3 (1.11%) showing the position of EVs in the Raman image. f) Overlay image showing excellent correspondence between the PC3 image of scores (h) with the SEM image (a). g) Raman spectrum in the 2700–3200  $\text{cm}^{-1}$  region corresponding to the PC1 displaying a  $\nu(\text{CH})$  stretching region of the cyanoacrylate glue with a characteristic peak at 2944  $\text{cm}^{-1}$ . h) Raman image of scores on PC1 (96.08%) showing the position of the glue particles in the Raman image. i) Overlay image showing excellent correspondence between the PC1 image of scores on PC1 (e) with the SEM image presented in (a).



retrieve objects of interest after transferring the stainless steel substrates between different instruments.

Fig. 6 presents the images of this multi-modal analysis, for the individual techniques as well as overlaid images. Noteworthy, a very good correlation exists between the images acquired with the individual techniques, with similar patterns observed in all 3 techniques (Fig. 6c, f, and i). Surprisingly, SEM imaging (Fig. 6a) revealed the presence of two types of particles, which could easily be distinguished based on their morphology and size: on one hand, small and elongated objects with an aspect ratio of approximately 1:7, and, on the other hand, compact, solidified crystalline particles with irregular shapes and well-defined edges, and with a height comparable to their lateral size. The larger particles were identified as cyanoacrylate glue particles, while the smaller particles were captured tdEVs, which was confirmed by Raman imaging (*vide infra*). Glue particles are presumably created upon release of the last PDMS device used to fabricate the navigation markers. In SEM, tdEVs present a much lower contrast than glue particles due to differences in molecular density.

Multivariate analysis of the Raman data by PCA performed in the high frequency region (2700 and 3200  $\text{cm}^{-1}$ ) as before confirms the presence of distinct populations of objects on the stainless steel substrates, whose Raman profile was distinct enough, as observed from the loading vectors PC3 (for tdEVs) and PC1 (for glue particles), respectively, in Fig. 6d and g. Measurements were conducted here on single EVs captured on the surface, and the signal-to-noise ratio was better in the high frequency region, which was therefore solely considered for data analysis. Yet, it allowed distinguishing tdEVs from other particles. As before, a clear Raman peak was found in the PC3 (Fig. 6d) loading at 2851  $\text{cm}^{-1}$ , which corresponds to the  $\text{CH}_2$  symmetric stretch of lipids, and a lipid-protein band between 2850 and 2950  $\text{cm}^{-1}$ , which is characteristic of EVs. These bands were absent in the PC1 loading, and are indeed not expected for cyanoacrylate (glue) particles. In contrast, the PC1 loading (Fig. 6g) presented a CH stretching region with a prominent peak at 2944  $\text{cm}^{-1}$  and a CN stretching region with a peak at around 2247  $\text{cm}^{-1}$ , which are both characteristic of cyanoacrylate glue.<sup>63</sup> It is worth noticing that the optical contrast of the images of scores is superior to the electron contrast in the SEM images, which clearly highlights the added value of correlative SEM-Raman imaging. The Raman images of the PC3 and PC1 scores in Fig. 6e and h reveal the respective distribution of the EVs and glue particles.

As a last analytical modality, AFM was employed to characterize the objects captured on the surface. Although AFM is typically slower than SEM, its resolution is higher, which allows detecting both more and smaller particles compared to the two other techniques. The resolution of particles below 0.5  $\mu\text{m}$  in SEM is complicated by the low contrast in absence of gold coating of the sample, whereas it became apparent only from AFM analysis that the majority of particles is in fact smaller than 120 nm (see Fig. 5c). Moreover, AFM provides

quasi-3D morphological information, which is of great interest to characterize the height of the captured EVs. Given also the low contrast in SEM due to the low acceleration voltages, the AFM data is altogether more suitable for studying the size distribution of captured EVs (Fig. 5c). Fig. 6b presents an AFM image corresponding to the previously discussed Raman and SEM images, and Fig. 6c an overlay image of the AFM and SEM data, showing good agreement between the data acquired by both techniques. In future studies, AFM could also be considered to examine the mechanical properties of the captured EVs (*e.g.*, by nanoindentation<sup>64</sup>).

Altogether, data acquired by AFM are fully in line with both Raman and SEM data, and they all demonstrate the specific capture of tdEVs by the covalently bound antibodies on the stainless steel substrates.

## Conclusion

We reported here a platform for the selective capture of tumor derived EVs (tdEVs) followed by their multi-modal analysis using SEM, Raman and AFM imaging to correlate size, morphological and chemical information at the individual EV level. Stainless steel, selected here for its suitability for all three imaging techniques, was first chemically modified with a CDPA monolayer onto which anti-EpCAM antibodies targeting tumor-derived EVs were immobilized. IRRAS and XPS characterization of the CDPA-functionalized surfaces revealed a densely packed and well-ordered monolayer, and XPS confirmed proper immobilization of the antibodies. Furthermore, EVs isolated from LNCaP prostate cancer cell lines were successfully captured on the antibody-conjugated stainless steel substrates, and successively analyzed using Raman spectroscopy, SEM and AFM. The integration of navigation markers on the stainless steel substrates after EV capture was instrumental here to track back individual EVs between the different analytical techniques. However, their fabrication using cyanoacrylate injected in patterned PDMS channels resulted in the creation of glue particles, which were detected together with the EVs. In future work, therefore, such navigation markers should be machined in the substrate and not onto the substrate to alleviate these contamination issues. Nonetheless, good agreement was found between the three techniques considered here, with excellent overlay of the images acquired by the individual modalities.

As a proof of concept, in this paper, tdEVs isolated from cancerous cell lines were captured and analyzed. As a next step, the same platform will be challenged with more complex samples, such as blood samples, after implementation of anti-fouling moieties, *e.g.*, based on polyethylene glycol. Furthermore, the proposed multi-modal approach can easily be expanded in the future to other optical (*e.g.*, confocal fluorescence microscopy or infrared spectroscopy), electron (*e.g.*, energy-dispersive X-ray spectroscopy) and probe (*e.g.*, force spectroscopy) microscopy techniques as well as other analysis techniques, *e.g.*, surface plasmon resonance (SPR) and mass spectroscopy (MS).



## Conflicts of interest

C. Otto declares a potential conflict of interest as a managing director of the company Hybriscan Technologies B.V. ([www.hybriscan.com](http://www.hybriscan.com)).

## Acknowledgements

The authors would like to thank Naoual Ouazzani Chahdi for her experimental contribution. This work is part of the Perspectief Program Cancer ID with project numbers 14193 and 14196, which is funded by the Netherlands Organization for Scientific Research (NWO) and co-financed by JEOL Europe B.V., Hybriscan Technologies B.V., Aquamarijn Micro Filtration B.V. and Lionix International B.V.

## References

- M. Poudineh, E. H. Sargent, K. Pantel and S. O. Kelley, *Nat. Biomed. Eng.*, 2018, 2, 72–84.
- R. Vaidyanathan, R. H. Soon, P. Zhang, K. Jiang and C. T. Lim, *Lab Chip*, 2018, 11–34.
- C. Alix-Panabières and K. Pantel, *Clin. Chem.*, 2013, 59, 110–118.
- F. A. W. Coumans, S. T. Ligthart, J. W. Uhr and L. W. M. M. Terstappen, *Clin. Cancer Res.*, 2012, 18, 5711–5718.
- F. Coumans, G. Van Dalum and L. W. M. M. Terstappen, *Cytometry, Part A*, 2018, 1197–1201.
- A. Nanou, F. A. W. Coumans, G. van Dalum, L. L. Zeune, D. Dolling, W. Onstenk, M. Crespo, M. S. Fontes, P. Rescigno, G. Fowler, P. Flohr, C. Brune, S. Sleijfer, J. S. de Bono and L. W. M. M. Terstappen, *Oncotarget*, 2018, 9, 19283–19293.
- M. Yáñez-Mó, P. R. M. Siljander, Z. Andreu, A. B. Zavec, F. E. Borràs, E. I. Buzas, K. Buzas, E. Casal, F. Cappello, J. Carvalho, E. Colás, A. Cordeiro-Da Silva, S. Fais, J. M. Falcon-Perez, I. M. Ghobrial, B. Giebel, M. Gimona, M. Graner, I. Gursel, M. Gursel, N. H. H. Heegaard, A. Hendrix, P. Kierulf, K. Kokubun, M. Kosanovic, V. Kralj-Iglic, E. M. Krämer-Albers, S. Laitinen, C. Lässer, T. Lener, E. Ligeti, A. Line, G. Lipps, A. Llorente, J. Lötvall, M. Manček-Keber, A. Marcilla, M. Mittelbrunn, I. Nazarenko, E. N. M. Nolte-’t Hoen, T. A. Nyman, L. O’Driscoll, M. Olivan, C. Oliveira, É. Pállinger, H. A. Del Portillo, J. Reventós, M. Rigau, E. Rohde, M. Sammar, F. Sánchez-Madrid, N. Santarém, K. Schallmoser, M. S. Ostfeld, W. Stoorvogel, R. Stukelj, S. G. Van Der Grein, M. H. Vasconcelos, M. H. M. Wauben and O. De Wever, *J. Extracell. Vesicles*, 2015, 4, 1–60.
- V. Sunkara, H.-K. Woo and Y.-K. Cho, *Analyst*, 2016, 141, 371–381.
- A. Liga, A. D. B. Vliegthart, W. Oosthuizen, J. W. Dear and M. Kersaudy-Kerhoas, *Lab Chip*, 2015, 15, 2388–2394.
- B. György, T. G. Szabó, M. Pásztói, Z. Pál, P. Misják, B. Aradi, V. László, É. Pállinger, E. Pap, Á. Kittel, G. Nagy, A. Falus and E. I. Buzás, *Cell. Mol. Life Sci.*, 2011, 68, 2667–2688.
- R. Xu, D. W. Greening, H. Zhu, N. Takahashi and R. J. Simpson, *J. Clin. Invest.*, 2016, 126, 1152–1162.
- E. Reátegui, K. E. Van Der Vos, C. P. Lai, M. Zeinali, N. A. Atai, B. Aldikacti, F. P. Floyd, A. Khankhel, V. Thapar, F. H. Hochberg, L. V. Sequist, B. V. Nahed, B. Carter, M. Toner, L. Balaj, D. Ting, X. O. Breakefield and S. L. Stott, *Nat. Commun.*, 2018, 9, 2018.
- Q. Zhu, M. Heon, Z. Zhao and M. He, *Lab Chip*, 2018, 18, 1690–1703.
- G. Raposo and W. Stoorvogel, *J. Cell Biol.*, 2013, 200, 373–383.
- H. Im, H. Shao, Y. Il Park, V. M. Peterson, C. M. Castro, R. Weissleder and H. Lee, *Nat. Biotechnol.*, 2014, 32, 490–495.
- K. W. Witwer, E. I. Buzás, L. T. Bemis, A. Bora, C. Lässer, J. Lötvall, E. N. Nolte-’t Hoen, M. G. Piper, S. Sivaraman, J. Skog, C. Théry, M. H. Wauben and F. Hochberg, *J. Extracell. Vesicles*, 2013, 2, 2013.
- Y. Yuana, A. N. Böing, A. E. Grootemaat, E. van der Pol, C. M. Hau, P. Cizmar, E. Buhr, A. Sturk and R. Nieuwland, *J. Extracell. Vesicles*, 2015, 4, 2015.
- B. J. Tauro, D. W. Greening, R. A. Mathias, H. Ji, S. Mathivanan, A. M. Scott and R. J. Simpson, *Methods*, 2012, 56, 293–304.
- Y. Yoshioka, N. Kosaka, Y. Konishi, H. Ohta, H. Okamoto, H. Sonoda, R. Nonaka, H. Yamamoto, H. Ishii, M. Mori, K. Furuta, T. Nakajima, H. Hayashi, H. Sugisaki, H. Higashimoto, T. Kato, F. Takeshita and T. Ochiya, *Nat. Commun.*, 2014, 5, 3591.
- E. Willms, C. Cabañas, I. Mäger, M. J. A. Wood and P. Vader, *Front. Immunol.*, 2018, 9, 2018.
- S. S. Kanwar, C. J. Dunlay, D. M. Simeone and S. Nagraath, *Lab Chip*, 2014, 14, 1891–1900.
- N. Koliha, Y. Wiencek, U. Heider, C. Jüngst, N. Kladt, S. Krauthäuser, I. C. D. Johnston, A. Bosio, A. Schauss and S. Wild, *J. Extracell. Vesicles*, 2016, 5, 2016.
- S. Yadav, K. Boriachek, M. N. Islam, R. Lobb, A. Möller, M. M. Hill, M. S. Al Hossain, N. T. Nguyen and M. J. A. Shiddiky, *ChemElectroChem*, 2017, 4, 967–971.
- S. C. Guo, S. C. Tao and H. Dawn, *J. Extracell. Vesicles*, 2018, 7, 1–16.
- F. A. W. Coumans, A. R. Brisson, E. I. Buzas, F. Dignat-George, E. E. E. Drees, S. El-Andaloussi, C. Emanuelli, A. Gasecka, A. Hendrix, A. F. Hill, R. Lacroix, Y. Lee, T. G. Van Leeuwen, N. Mackman, I. Mäger, J. P. Nolan, E. Van Der Pol, D. M. Pegtel, S. Sahoo, P. R. M. Siljander, G. Sturk, O. De Wever and R. Nieuwland, *Circ. Res.*, 2017, 120, 1632–1648.
- H. Im, K. Lee, R. Weissleder, H. Lee and C. M. Castro, *Lab Chip*, 2017, 17, 2892–2898.
- J. C. Contreras-Naranjo, H. J. Wu and V. M. Ugaz, *Lab Chip*, 2017, 17, 3558–3577.
- C. L. Hisey, K. D. P. Dorayappan, D. E. Cohn, K. Selvendiran and D. J. Hansford, *Lab Chip*, 2018, 18, 3144–3153.
- T. G. Kormelink, G. J. A. Arkesteijn, F. A. Nauwelaers, G. van den Engh, E. N. M. Nolte-’t Hoen and M. H. M. Wauben, *Cytometry, Part A*, 2016, 89, 135–147.
- Y. Yuana, T. H. Oosterkamp, S. Bahatyrova, B. Ashcroft, P. Garcia Rodriguez, R. M. Bertina and S. Osanto, *J. Thromb. Haemostasis*, 2010, 8, 315–323.



- 31 E. van der Pol, A. Sturk, T. van Leeuwen, R. Nieuwland, F. Coumans, F. Mobarrez, G. Arkesteijn, M. Wauben, P. R. M. Siljander, V. Sánchez-López, R. Otero-Candelera, L. A. Ramón, S. Dolz, V. Vila, N. Mackman, J. Geddings, F. Mullier, N. Bailly, J. Y. Han, H. C. Kwaan, I. M. Weiss, E. I. Buzás, E. Pállinger, P. Harrison, J. Kraan, B. D. Hedley, A. LazoLangner, A. Enjeti, P. J. Norris, C. Paris, S. Susen, A. Bonnefoy, I. Delorme, W. L. Chandler, C. Hau, H. C. D. Aass, D. Connor, X. Wu, R. Dragovic, L. M. Uotila, R. Lacroix and S. Robert, *J. Thromb. Haemostasis*, 2018, **16**, 1236–1245.
- 32 P. Zhang, J. Crow, D. J. Lella, X. Zhou, G. Samuel, A. K. Godwin and Y. Zeng, *Lab Chip*, 2018, **18**, 3790–3801.
- 33 P. Zhang, M. He and Y. Zeng, *Lab Chip*, 2016, **16**, 3033–3042.
- 34 N. Sebaihi, B. De Boeck, Y. Yuana, R. Nieuwland and J. Pétry, *Meas. Sci. Technol.*, 2017, **28**, 8pp.
- 35 W. Lee, A. Nanou, L. Rikkert, F. A. W. Coumans, C. Otto, L. W. M. M. Terstappen and H. L. Offerhaus, *Anal. Chem.*, 2018, **90**, 11290–11296.
- 36 V. Shpacovitch and R. Hergenröder, *Anal. Chim. Acta*, 2018, **1005**, 1–15.
- 37 S. Obeid, A. Ceroi, G. Mourey, P. Saas, C. Elie-Caille and W. Boireau, *Biosens. Bioelectron.*, 2017, **93**, 250–259.
- 38 G. Pocsfalvi, C. Stanly, A. Vilasi, I. Fiume, G. Capasso, L. Turiák, E. I. Buzas and K. Vékey, *Mass Spectrom. Rev.*, 2015, **35**, 3–21.
- 39 H. Shao, J. Chung, L. Balaj, A. Charest, D. D. Bigner, B. S. Carter, F. H. Hochberg, X. O. Breakefield, R. Weissleder and H. Lee, *Nat. Med.*, 2012, **18**, 1835–1840.
- 40 I. Tatischeff, E. Larquet, J. M. Falcón-Pérez, P.-Y. Turpin and S. G. Kruglik, *J. Extracell. Vesicles*, 2012, **1**, 19179.
- 41 C. Krafft, K. Wilhelm, A. Eremin, S. Nestel, N. von Bubnoff, W. Schultze-Seemann, J. Popp and I. Nazarenko, *Nanomedicine*, 2017, **13**, 835–841.
- 42 N. Eswaran, V. A. Sundaram, K. A. Rao and S. T. Balasundaram, *3 Biotech*, 2018, **8**, 1–6.
- 43 K. A. Kondratov, T. A. Petrova, V. Yu Mikhailovskii, A. N. Ivanova, A. A. Kostareva and A. V. Fedorov, *Cell tissue biol.*, 2017, **11**, 181–190.
- 44 F. J. Timmermans and C. Otto, *Rev. Sci. Instrum.*, 2015, **86**, 2015.
- 45 A. Enciso-Martinez, F. J. Timmermans, A. Nanou, L. W. M. M. Terstappen and C. Otto, *Analyst*, 2018, **143**, 4495–4502.
- 46 S. Sharma, H. I. Rasool, V. Palanisamy, C. Mathisen, M. Schmidt, D. T. Wong and J. K. Gimzewski, *ACS Nano*, 2010, **4**, 1921–1926.
- 47 M. Kosian, M. M. J. Smulders and H. Zuilhof, *Langmuir*, 2016, **32**, 1047–1057.
- 48 A. Raman, M. Dubey, I. Gouzman and E. S. Gawalt, *Langmuir*, 2006, **22**, 6469–6472.
- 49 G. Tizazu, A. M. Adawi, G. J. Leggett and D. G. Lidzey, *Langmuir*, 2009, **25**, 10746–10753.
- 50 G. T. Hermanson, *Bioconjugate Techniques*, Academic Press, 2nd edn, 2013.
- 51 E. van der Pol, F. A. W. Coumans, A. E. Grootemaat, C. Gardiner, I. L. Sargent, P. Harrison, A. Sturk, T. G. van Leeuwen and R. Nieuwland, *J. Thromb. Haemostasis*, 2014, **12**, 1182–1192.
- 52 H. Abdi and L. J. Williams, *Wiley Interdiscip. Rev. Comput. Stat.*, 2010, **2**, 433–459.
- 53 J. Ter Maat, R. Regeling, C. J. Ingham, C. A. G. M. Weijers, M. Giesbers, W. M. De Vos and H. Zuilhof, *Langmuir*, 2011, **27**, 13606–13617.
- 54 M. D. Porter, T. B. Bright, D. L. Allara and C. E. Chidsey, *J. Am. Chem. Soc.*, 1987, **109**, 3559–3568.
- 55 R. Maoz and J. Sagiv, *J. Colloid Interface Sci.*, 1984, **100**, 465–496.
- 56 A. Debrassi, E. Roeven, S. Thijssen, L. Scheres, W. M. De Vos, T. Wennekes and H. Zuilhof, *Langmuir*, 2015, **31**, 5633–5644.
- 57 R. Arnold, W. Azzam, A. Terfort and C. Wöll, *Langmuir*, 2002, **18**, 3980–3992.
- 58 C. D. Bain and G. M. Whitesides, *J. Phys. Chem.*, 1989, **93**, 1670–1673.
- 59 P. E. Laibinis, C. D. Bain and G. M. Whitesides, *J. Phys. Chem.*, 1991, **95**, 7017–7021.
- 60 Z. Movasaghi, S. Rehman and I. U. Rehman, *Appl. Spectrosc. Rev.*, 2007, **42**, 493–541.
- 61 E. Van Der Pol, A. G. Hoekstra, A. Sturk, C. Otto, T. G. Van Leeuwen and R. Nieuwland, *J. Thromb. Haemostasis*, 2010, **8**, 2596–2607.
- 62 F. J. Timmermans, L. Chang, H. A. G. M. van Wolferen, A. T. M. Lenferink and C. Otto, *Opt. Lett.*, 2017, **42**, 1337–1340.
- 63 H. G. M. Edwards and J. S. Day, *J. Raman Spectrosc.*, 2004, **35**, 555–560.
- 64 B. W. H. Roos and G. J. L. Wuite, *Adv. Mater.*, 2009, 1187–1192.

